In the US, Desirudin (desirudin systemic) is a member of the drug class thrombin inhibitors and is used to treat Deep Vein Thrombosis, Prophylaxis.
US matches:
- Desirudin
- Desirudin Subcutaneous
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
B01AE01
CAS registry number (Chemical Abstracts Service)
0120993-53-5
Chemical Formula
C287-H440-N80-O110-S6
Molecular Weight
6963
Therapeutic Category
Anticoagulant agent: Direct thrombin inhibitor
Chemical Name
Hirudin (Hirudo medicinalisisoform HV1), 63-desulfo-
Foreign Names
- Desirudinum (Latin)
- Desirudin (German)
- Désirudine (French)
- Desirudina (Spanish)
Generic Names
- Desirudin (OS: BAN, USAN)
- Désirudine (OS: DCF)
- 63-Desulfohirudin (IS: WHO)
- CGP 39393 (IS: Ciba-Geigy)
Brand Names
- Iprivask
Aventis, United States - Revasc
Canyon, Luxembourg; Novartis, Slovakia; Sanofi-Aventis S.A.U., Spain
International Drug Name Search
Glossary
BAN | British Approved Name |
DCF | Dénomination Commune Française |
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.